Anti-drug antibodies in psoriasis: A critical evaluation of clinical significance and impact on treatment response

Expert Review of Clinical Immunology

Volumn 9, Issue 10, 2013, Pages 949-958

  Hsu, Leeyen ^a   Armstrong, April W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adalimumab; anti drug antibodies; etanercept; infliximab; methotrexate; psoriasis; ustekinumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ANTIBODY PRODUCTION; ANTIBODY TITER; CROSS LINKING; DRUG EFFICACY; IMMUNOMODULATION; PSORIASIS; REVIEW; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOMODULATION; METHOTREXATE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84886937924     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.836060     Document Type: Review

References (75)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N. Engl J. Med. 332(9), 581-588 (1995).
2. Fitzpatrick TB. Dermatology in General Medicine. McGraw-Hill, NY, USA (1993).
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137(3), 280-284 (2001).
4. Griffiths TW, Griffiths CE, Voorhees JJ. Immunopathogenesis and immunotherapy of psoriasis. Dermatol. Clin. 13(4), 739-749 (1995).
5. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 370(9583), 263-271 (2007).
6. Nagano K, Hori K, Nagane T et al. Effect of tumour necrosis factor in the mouse-tail model of psoriasis. Arch. Dermatol. Res. 282(7), 459-462 (1990).
7. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96(1), 146-151 (1994).
8. Mussi A, Bonifati C, Carducci M et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J. Biol. Regul. Homeost. Agents 11(3), 115-118 (1997).
9. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349(21), 2014-2022 (2003).
10. Gordon KB, Gottlieb AB, Leonardi CL et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J. Dermatol. Treat. 17(1), 9-17 (2006).
11. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366(9494), 1367-1374 (2005).
12. Weinberg JM, Bottino CJ, Lindholm J, Buchholz R. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. J. Drugs Dermatol. 4(5), 544-555 (2005).
13. Wolbink GJ, Aarden LA, Dijkmans BA Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol. 21(3), 211-215 (2009).
14. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MABS 2(3), 256-265 (2010).
15. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 36(1), 3-10 (2005).
16. ENBREL [Prescribing Information]. Seattle, WA: Immunex Corporation, 2012.
17. REMICADE [Prescribing Information]. Malvern, PA: Centocor Inc, 2013.
18. HUMIRA [Prescribing Information]. North Chicago, IL; Abbott Laboratories, 2013.
19. STERLARA [Prescribing Information]. Malvern, PA: Centocor Inc, 2013.
20. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664), 633-640 (2009).
21. Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7(9), 796-804 (2008).
22. Tada Y, Asahina A, Takekoshi T et al. Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A. Br. J. Dermatol. 154(6), 1180-1183 (2006).
23. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13(5), 715-725 (2000).
24. Kimball AB, Papp KA, Wasfi Y et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J. Eur. Acad. Dermatol. Venereol. (2012).
25. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled Phase III trial. J. Am. Acad. Dermatol. 58(1), 106-115 (2008).
26. Lecluse LL, Driessen RJ, Spuls PI et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch. Dermatol. 146(2), 127-132 (2010).
27. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 56(1), 31 e31-e15 (2007).
28. Leonardi C, Strober B, Gottlieb AB et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.J. Drugs Dermatol. 9(8), 928-937 (2010).
29. Papp KA, Tyring S, Lahfa M et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152(6), 1304-1312 (2005).
30. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch. Dermatol. 143(6), 719-726 (2007).
31. Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single centre, cohort study. Br. J. Dermatol. (2013).
32. Dore RK, Mathews S, Schechtman J et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25(1), 40-46 (2007).
33. Keystone EC, Schiff MH, Kremer JM et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 50(2), 353-363 (2004).
34. Adisen E, Aral A, Aybay C, Gurer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. J. Dermatol. 37(8), 708-713 (2010).
35. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51(4), 534-542 (2004).
36. Gottlieb AB, Kalb RE, Blauvelt A et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J. Am. Acad. Dermatol. 67(4), 642-650 (2012).
37. Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br. J. Dermatol. 165(6), 1355-1358 (2011).
38. Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients.J. Drugs Dermatol. 5(3), 251-254 (2006).
39. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J. Dermatol. 40(1), 39-42 (2013).
40. Torii H, Nakagawa H, Japanese Infliximab Study I. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J. Dermatol. 38(4), 321-334 (2011).
41. Torii H, Nakagawa H, Japanese Infliximab Study i. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J. Dermatol. Sci. 59(1), 40-49 (2010).
42. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9), 1552-1563 (1998).
43. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 46(12), 1828-1834 (2007).
44. de Vries MK, Brouwer E, van der Horst-Bruinsma IE et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann. Rheum. Dis. 68(11), 1787-1788 (2009).
45. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56(9), 1226-1231 (2007).
46. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl J. Med. 348(7), 601-608 (2003).
47. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl J. Med. 337(15), 1029-1035 (1997).
48. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002).
49. Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54(3), 711-715 (2006).
50. de Vries MK, Wolbink GJ, Stapel SO et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann. Rheum. Dis. 66(9), 1252-1254 (2007).
51. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357(9271), 1842-1847 (2001).
52. Vena G, Loconsole F, Mastrandrea V, Buquicchio R, Cassano N. Therapeutic hotline: re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis. Dermatol. Ther. 23(2), 199-202 (2010).
53. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124(4), 917-924 (2003).
54. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl J. Med. 350(9), 876-885 (2004).
55. Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab MSG. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J. Dermatol. 37(4), 299-310 (2010).
56. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48(1), 35-45 (2003).
57. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol. Int. 27(3), 269-274 (2007).
58. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66(7), 921-926 (2007).
59. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56(9), 1232-1239 (2007).
60. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130(2), 323-333; quiz 591 (2006).
61. Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl J. Med. 362(2), 118-128 (2010).
62. Papp KA, Langley RG, Lebwohl M et al Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625), 1675-1684 (2008).
63. Tsai TF, Ho JC, Song M et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a Phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J. Dermatol. Sci. 63(3), 154-163 (2011).
64. Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl J. Med. 356(6), 580-592 (2007).
65. Kauffman CL, Aria N, Toichi E et al A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.J. Invest. Dermatol. 123(6), 1037-1044 (2004).
66. Hart MH, de Vrieze H, Wouters D et al. Differential effect of drug interference in immunogenicity assays. J. Immunol. Methods 372(1-2), 196-203 (2011).
67. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res. Ther. 12(5), 217 (2010).
68. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14), 1460-1468 (2011).
69. Rispens T, de Vrieze H, de Groot E et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J. Immunol. Methods 375(1-2), 93-99 (2012).
70. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann. Rheum. Dis. PMID:23223420 (2012) (Epub ahead of print).
71. Baert F, De Vos M, Louis E, Vermeire S, Belgian IBDRG. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol. Belg. 70(2), 163-170 (2007).
72. van Schouwenburg PA, van de Stadt LA, de Jong RN et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann. Rheum. Dis. 72(1), 104-109 (2013).
73. Garces S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann. Rheum. Dis. PMID:23666932 (2013) (Epub ahead of print).
74. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann. Rheum. Dis. 69(5), 817-821 (2010).
75. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 60(8) 2541-2542 (2009).